Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 226-231

  Yang, L ^a   Guo, T ^b   Xia, D Y ^b   Zhao, L S ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHENYANG NORTHERN HOSPITAL   (China)

Author keywords

E 3174; Ethnicity; High performance liquid chromatography fluorescence; Losartan; Pharmacokinetics

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; DRUG METABOLITE; LOSARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINA; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POPULATION RESEARCH; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; TETRAZOLES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84857996362     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01279.x     Document Type: Article

References (25)

1. Borghi C, Ertek S LIFE (losartan intervention for endpoint reduction in hypertension) study and its substudies. International Congress Series, 2007;1303:129-137.
2. Polinko M, Riffel K, Song HC, Lo MW Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2003;33:73-84. (Pubitemid 37297519)
3. Burnier M Angiotensin II type 1 receptor blockers. Circulation, 2001;103:904-912. (Pubitemid 32163892)
4. Sica DA, Gehr TWB, Ghosh S Clinical pharmacokinetics of losartan. Clinical pharmacokinetics, 2005;44:797-814. (Pubitemid 41126929)
5. Munafo A, Christen Y, Nussberger J et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clinical Pharmacology and Therapeutics, 1992;51:513-521.
6. Yeung PKF, Pollak PT, Jamieson A, Smith GJ, Fice D Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. International Journal of Pharmaceutics, 2000;204:17-22.
7. Soldner A, Spahn-Langguth H, Mutschler E HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. Journal of Pharmaceutical and Biomedical Analysis, 1998;16:863-873. (Pubitemid 28097414)
8. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E Role of CYP2C9 polymorphism in losartan oxidation. Drug Metabolism and Disposition, 2001;29:1051-1056. (Pubitemid 32605922)
9. Kaukonen KM, Olkkola KT, Neuvonen PJ Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. European Journal of Clinical Pharmacology, 1998;53:445-449. (Pubitemid 28154745)
10. Food and Drug Administration Guidance on ethnic factors in the acceptability of foreign clinical data. Federal Register, 1998;63:31790-31796.
11. Balant LP, Balant-Gorgia EA Cultural differences: implications on drug therapy and global drug development. International journal of clinical pharmacology and therapeutics, 2000;38:47-52. (Pubitemid 30077978)
12. Guo T, Sun WJ, Xia DY, Zhao LS The pharmacokinetics of fluconazole in healthy Chinese adult volunteers: influence of ethnicity and gender. Journal of Clinical Pharmacy and Therapeutics, 2009;34:1-7.
13. Yu MS, Qiu XF, Xue JL et al. Study on the mtDNA polymorphism in Han, Urghur, Hasake and Hui nationalities. The Journal of The Library Science In China, 1988;18:60-70.
14. Zhao TM, Zhang GL, Yuan YD, Du RF Genetic distances estimated on the basis of HLA. Acta Anthropologica Sinica, 1984;3:166-169.
15. Chang XY, Guo T, Xia DY Pharmacokinetics of Tinidazole in Chinese subjects: comparison of Mongolian, Korean, Hui, Uighur and Han nationalities. Journal of Pharmacy and Pharmaceutical Sciences, 2009;12:175-180.
16. Yang L, Xia DY, Guo T Simultaneous Determination of Losartan and its Major Metabolite, E-3174, in Human Plasma by HPLC-Fluorescence Method. China Pharmacy, 2009;20:2509-2511.
17. Chen ZY, Sun RY DAS software for pharmacological calculation. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002;7:562-564.
18. SPSS Inc (2008) SPSS Base User Guide 16.0. Chicago Illinois: SPSS Inc.
19. Liu QG, Zhang FL Application of SPSS in medical science. Inner Mongolia University Publishing House, 2002;9:75-80.
20. Chen XQ, Jin YY, Tang G (2003) Newly Compiled Materia Media [M], Vol. 16, 15th edn. Beijing: People's Medical Publishing House, 125-126.
21. Stearns RA, Chakravarty PK, Chen R, Chiu SH Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metabolism and Disposition, 1995;23:207-215.
22. Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP Oxidation of the angiotensin II receptor antagonist losartan (DuP7.53) in human liver microsomes: role of cytochrome P4503A(4) in formation of the active metabolite E3174. Drug Metabolism and Disposition, 1995;23:285-289.
23. Takanashi K, Tainaka H, Kobayashi K, Yasurnori T, Hosakawa M, Chiba K CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics, 2000;10:95-104. (Pubitemid 30193071)
24. Yasar U, Forslund-Bergengren C, Tybring G et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clinical Pharmacology and Therapeutics, 2002;71:89-98. (Pubitemid 34124042)
25. Mizutani T PM Frequencies of Major CYPs in Asians and Caucasians. Drug Metabolism Reviews, 2003;35:99-106. (Pubitemid 37048293)